アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

aurobindo pharma limited - quinapril hydrochloride (unii: 33067b3n2m) (quinaprilat - unii:34ssx5lde5), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - quinapril 10 mg - hypertension quinapril and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with quinapril and hydrochlorothiazide tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joi

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

physicians total care, inc. - quinapril hydrochloride (unii: 33067b3n2m) (quinapril - unii:rj84y44811) - quinapril hydrochloride 5 mg - quinapril tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. in using quinapril, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. available data are insufficient to show that quinapril does not have a similar risk (see warnings ) black patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. it should also be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. quinapril tablels are contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an ace inhibitor.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - quinapril hydrochloride, quantity: 21.664 mg (equivalent: quinapril, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; crospovidone; magnesium carbonate hydrate; colloidal anhydrous silica; povidone; calcium sulfate dihydrate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - quinapril hydrochloride, quantity: 10.832 mg (equivalent: quinapril, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium carbonate hydrate; crospovidone; colloidal anhydrous silica; povidone; magnesium stearate; calcium sulfate dihydrate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - quinapril hydrochloride, quantity: 5.416 mg (equivalent: quinapril, qty 5 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; povidone; crospovidone; calcium sulfate dihydrate; magnesium stearate; magnesium carbonate hydrate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - quinapril hydrochloride (unii: 33067b3n2m) (quinaprilat - unii:34ssx5lde5) - quinapril 20 mg - hypertension quinapril tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with quinapril tablets, usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention,

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

aurobindo pharma limited - quinapril hydrochloride (unii: 33067b3n2m) (quinaprilat - unii:34ssx5lde5) - quinapril 5 mg - hypertension quinapril tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with quinapril tablets, usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, d

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

sun pharmaceutical industries limited - quinapril hydrochloride (unii: 33067b3n2m) (quinapril - unii:rj84y44811) - quinapril hydrochloride 5 mg - hypertension quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. in using quinapril hydrochloride tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. available data are insufficient to show that quinapril hydrochloride tablets do not have a similar risk (see warnings). angioedema in black patients black patients receiving ace inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. it should also be noted that in controlled clinical trials ace inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. quinapril hydrochloride tablets are contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous tr

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - quinapril hydrochloride (unii: 33067b3n2m) (quinaprilat - unii:34ssx5lde5) - quinapril 20 mg - hypertension quinapril tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with quinapril tablets, usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, d

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

proficient rx lp - quinapril hydrochloride (unii: 33067b3n2m) (quinaprilat - unii:34ssx5lde5) - quinapril 10 mg - hypertension quinapril tablets, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with quinapril tablets, usp. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, d